News

Filter

Current filters:

BiotechnologySanofi

1 to 9 of 127 results

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

Voyager inks up to $845 million deal with Genzyme on novel CNS products

Voyager inks up to $845 million deal with Genzyme on novel CNS products

12-02-2015

US gene therapy start-up company Voyager Therapeutics has entered into a major strategic collaboration…

BiotechnologyGenzymeLicensingNeurologicalResearchSanofiUSAVoyager Therapeutics

Regeneron sees strong Eylea sales; financials beat expectations

Regeneron sees strong Eylea sales; financials beat expectations

10-02-2015

US biotech firm Regeneron Pharmaceuticals today announced financial results for the fourth quarter and…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron PharmaceuticalsSanofi

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

Sanofi granted European marketing authorization for Cerdelga in Gaucher disease

Sanofi granted European marketing authorization for Cerdelga in Gaucher disease

22-01-2015

French drug major Sanofi and its subsidiary Genzyme have been granted marketing authorization by the…

BiotechnologyCerdelgaGeneticsGenzymeRegulationSanofi

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

12-01-2015

French drug major Sanofi and US biotech company Regeneron have announced that the European Medicines…

alirocumabBiotechnologyCardio-vascularEuropeRegeneronRegulationSanofi

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

09-01-2015

French pharma major Sanofi and Regeneron Pharmaceuticals today announced that two new ODYSSEY trials,…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

US sales of Sanofi/Regeneron’s dupilumab for atopic dermatitis could exceed $1.3 billion by 2022, says analyst

04-12-2014

The first biologic to treat atopic dermatitis, French pharma major Sanofi (Euronext: SAN) and US biotech…

BiotechnologyDermatologicalsdupilumabMarkets & MarketingRegeneron PharmaceuticalsSanofiUSA

1 to 9 of 127 results

COMPANY SPOTLIGHT

Menarini

Back to top